The Medical Advisor

In this Article: Linoleic acid (LA) , a fat once rare in the human diet, now makes up as much as 25% of daily calories for many Americans and accumulates in fat tissue for years, disrupting metabolism and fueling chronic disease Even "clean" foods like chicken, pork, nuts, olive oil and avocado oil contain high levels of LA or are adulterated with vegetable oils, making it easy to exceed safe intake levels without realizing it LA doesn’t just stay in your fat; it breaks down into toxic compounds that damage your mitochondria, the energy factories in your cells, contributing to fatigue, insulin resistance and hormonal dysfunction Oils marketed as safer alternatives, like those from Zero Acre Farms, are genetically engineered and high in oleic acid, which causes similar mitochondrial damage and should also be avoided The most effective way to protect your health is to eliminate industrial veget...

Introduction There is increasing interest in the potential use of Ivermectin and Fenbendazole as cancer treatments. This guide compiles key resources—including research articles, protocols, and expert insights—exploring their possible roles in cancer therapy. Several case reports for fenbendazole, ivermectin and mebendazole have revealed promising effects of these drugs in human patients having variable types of cancers.  The present paper aimed to review recent trends in use of ivermectin, fenbendazole and mebendazole as new promising anti-cancer agents.   Ivermectin: Key Resources Ivermectin is one of the top non-standard or non-conventional drug for cancer. Informative Article and Videos June 10, 2024  - "15 minutes with Dr.Makis" - Episode 018: High Dose IVERMECTIN and CANCER 2024 Studies Baghli et al 2024 -  Targeting the Mitochondrial-Stem Cell Connection in Cancer Treatment: ...

With only one of the biopharma industry’s top 20 revenue companies seeing a year-over-year decline in sales, 2024 was a remarkable year of revenue growth for the industry. Compare that to 2023, when eight of the top 20 drugmakers experienced revenue declines. Six of the top 20 drugmakers had double-digit increases in 2024, compared to just two in 2023. Five others saw a revenue bump of between 7% and 9%, compared to two reaching those figures in 2023. For the second year in a row, Eli Lilly (32%) and Novo Nordisk (26%) posted Big Pharma's largest year-over-year sales bumps, though their positions were flipped from 2023 when Novo (31%) topped Lilly (20%). Expect the same form in 2025 as Lilly—boosted by sales of its diabetes and obesity drugs Moujaro and Zepbound— projects its sales to fall between $58 billion and $61 billion. At the midpoint of the projection, it would be a 32% increase, matching the sales boom it saw last ...